Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298778 | 0.81 | LMNA (0.38) | LMNAMAP3K14KDM4EALDH1A1HSD17B10 | |
| SCHEMBL15956594 | 0.77 | LMNA (0.42) | LMNAMAP3K14KDM4EALDH1A1HTT | |
| SCHEMBL2060081 | 0.77 | ALDH1A1 (0.51) | KDM4EALDH1A1CA1CA9HTT | |
| SCHEMBL13088423 | 0.77 | LMNA (0.40) | LMNAMAP3K14KDM4EALDH1A1TSHR | |
| SCHEMBL25262175 | 0.76 | LMNA (0.37) | LMNAMAP3K14KDM4ETSHRCYP3A4 | |
| SCHEMBL1396053 | 0.74 | LMNA (0.38) | LMNAMAP3K14KDM4ETSHRHSD17B10 | |
| SCHEMBL14104429 | 0.74 | CYP2D6 (0.43) | TSHRHSD17B10TP53MAPTCYP2C19 | |
| SCHEMBL1854385 | 0.74 | KDM4E (0.37) | LMNAMAP3K14KDM4EALDH1A1CA1 | |
| SCHEMBL15527837 | 0.74 | GAA (0.44) | LMNAKDM4EALDH1A1HTTTP53 | |
| SCHEMBL3311103 | 0.74 | LMNA (0.36) | LMNAMAP3K14KDM4ETSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8148523-B2 | Intermediates useful in preparing certain pyrrolotriazine compounds and a process for making the intermediates | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148523-B2 | Intermediates useful in preparing certain pyrrolotriazine compounds and a process for making the intermediates | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148523-B2 | Intermediates useful in preparing certain pyrrolotriazine compounds and a process for making the intermediates | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2011150356-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| EP-2111405-B1 | INTERMEDIATES USEFUL IN PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS AND A PROCESS FOR MAKING THE INTERMEDIATES | BRISTOL MYERS SQUIBB CO (US) | 2010-10-27 | — | — | EP | disclosed |
| EP-2111405-B1 | INTERMEDIATES USEFUL IN PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS AND A PROCESS FOR MAKING THE INTERMEDIATES | BRISTOL MYERS SQUIBB CO (US) | 2010-10-27 | — | — | EP | disclosed |
| EP-2111405-A1 | INTERMEDIATES USEFUL IN PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS AND A PROCESS FOR MAKING THE INTERMEDIATES | Brystol-Myers Squibb Company (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008086264-A1 | INTERMEDIATES USEFUL IN PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS AND A PROCESS FOR MAKING THE INTERMEDIATES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086264-A1 | INTERMEDIATES USEFUL IN PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS AND A PROCESS FOR MAKING THE INTERMEDIATES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130071415-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | LMNA 4684/4885MAP3K14 21/4885KDM4E 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.